Showing results (761-770 of 794) with videos related to

Sort By:
Pageof 80
European Urology|November 5, 2025
Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysisIrbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, Kunwer Sufyan Faisal, et al.
JCO Precision Oncology|July 8, 2026
Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III TrialsChristopher J Sweeney, Vrishab Krishna, Viswesh Krishna, et al.
Molecular Oncology|August 3, 2023
Pharmacological NF-κB inhibition decreases cisplatin chemoresistance in muscle-invasive bladder cancer and reduces cisplatin-induced toxicitiesRui M Gil da Costa, Christine Levesque, Daniella Bianchi-Frias, et al.
JAMA Oncology|January 25, 2019
Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell TumorsSaud H AlDubayan, Louise C Pyle, Marija Gamulin, et al.
European Urology|September 18, 2024
Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate CancerAdam B Weiner, Raag Agrawal, Nicholas K Wang, et al.
Genome Medicine|September 4, 2022
Accumulation of copy number alterations and clinical progression across advanced prostate cancerEmily Grist, Stefanie Friedrich, Christopher Brawley, et al.
The Lancet. Oncology|March 29, 2023
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trialChristopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
The New England Journal of Medicine|June 4, 2019
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate CancerIan D Davis, Andrew J Martin, Martin R Stockler, et al.
European Urology|May 25, 2021
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation TherapyChristopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
Nature Communications|December 16, 2025
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancerSoumyajit Roy, Yilun Sun, Maha Hussain, et al.
Pageof 80